Literature DB >> 24438158

Nasal septoplasty with submucosal diathermy to inferior turbinates improves symptoms at 3 months postoperatively in a study of one hundred and one patients.

A Enache1, A Lieder, W Issing.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24438158     DOI: 10.1111/coa.12219

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


× No keyword cloud information.
  5 in total

1.  Impact of Septal Correction on the Blood Pressure of Hypertensive Patients with Deviated Nasal Septum.

Authors:  S G Smitha; B Jagannath; Amrita Suzanne Mathew
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2015-02-17

2.  Improvement in minimal cross-sectional area and nasal-cavity volume occurs in different areas after septoplasty and radiofrequency therapy of inferior turbinates.

Authors:  Ann Helen Nilsen; Wenche Moe Thorstensen; Anne-Sofie Helvik; Staale Nordgaard; Vegard Bugten
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-05       Impact factor: 2.503

3.  A comparison of symptoms and quality of life before and after nasal septoplasty and radiofrequency therapy of the inferior turbinate.

Authors:  Ann Helen Nilsen; Anne-Sofie Helvik; Wenche Moe Thorstensen; Vegard Bugten
Journal:  BMC Ear Nose Throat Disord       Date:  2018-01-26

4.  Evaluation of strategies for increasing response rates to postal questionnaires in quality control of nasal septal surgery.

Authors:  Merete T Egeland; Magnus Tarangen; Olga Shiryaeva; Caryl Gay; Liv K Døsen; Rolf Haye
Journal:  BMC Res Notes       Date:  2017-06-02

5.  Nasal Airway Obstruction Study (NAIROS): a phase III, open-label, mixed-methods, multicentre randomised controlled trial of septoplasty versus medical management of a septal deviation with nasal obstruction.

Authors:  Katherine J Rennie; James O'Hara; Nikki Rousseau; Deborah Stocken; Denise Howel; Laura Ternent; Mike Drinnan; Alison Bray; Leila Rooshenas; David W Hamilton; Alison Steel; Tony Fouweather; Ann-Marie Hynes; Eva-Maria Holstein; Yemi Oluboyede; Alaa Abouhajar; Janet A Wilson; Sean Carrie
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.